Calixar, a Lyon, France-based biotech company, completed a €1m (US$1.1m) round of financing.
Backers included existing investors Siparex, Veymont Participations, INPG Entreprise SA – and regional business angels Health-Angels Rhône-Alpes, Savoie Angels and Grenoble Angels. Bpifrance, the French public investment bank, and the Banque Populaire supplemented this funding through repayable advance and specific credit supported by the European Union.
Led by Emmanuel Dejean, President & CEO, Calixar specializes in the native isolation of complex therapeutic targets and antigens. It currently owns 5 patents. Its approach allows to preserve the original structure and function of membrane proteins (GPCRs, Ion Channels, Transporters, Receptors, Anchors and Viral Proteins) providing solutions for pharmaceutical industries, biotechnology companies and academic teams to develop conformational antibodies, formulate new vaccines, carry out Structure Based Drug Discovery and/or HTS assays.
The company intends to use the funds to advance the development of new Influenza vaccines and high affinity antibodies to GPCRs, which will be available for partnership with the pharmaceutical industry by the second semester 2015.